{{noteTA|G1 = ME}}
{{Medical}} 
{{Infobox drug
| IUPAC_name = 2-amino-9-[(1''S'',3''R'',4''S'')-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-6,9-dihydro-3''H''-purin-6-one
| image = Entecavir.svg
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 142217-69-4
| ATC_prefix = J05
| ATC_suffix = AF10
| PubChem = 153941
| DrugBank = APRD00948
| CAS_number2_Ref = {{cascite|correct|CAS}}
| CAS_number2 =  209216-23-9
| DrugBank2_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank2 = DB00442
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII =  5968Y6H45M 
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04008
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 59902
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 713
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 135679
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8-/m0/s1
| smiles = O=C2/N=C(\Nc1n(cnc12)[C@@H]3C(=C)/[C@H](CO)[C@@H](O)C3)N
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = {{unbulleted list|YXPVEXCTPGULBZ-WQYNNSOESA-N|QDGZDCVAUDNJFG-FXQIFTODSA-N}}
| C=12 | H=15 | N=5 | O=3
| molecular_weight = 277.279 g/mol
| bioavailability = 
| protein_bound = 13%
| metabolism = 
| elimination_half-life = 128–149小时
| excretion = 肾脏 62–73%
| pregnancy_US = C
| legal_US = Rx-only
| routes_of_administration = 口服
| licence_EU =Baraclude
| licence_US =Entecavir
}}
<!-- Definition and medical uses -->
'''恩替卡韋'''（{{lang-en|Entecavir}}），是一種[[抗病毒藥物|抗病毒藥物]]，用以治療[[乙型肝炎病毒|B型肝炎病毒]]感染，常見的商用藥品名為'''貝樂克'''（{{lang-en|Baraclude}}）。同時患有[[艾滋病|愛滋病]]和[[乙型肝炎|B型肝炎]]的患者，不建議單獨使用本品，應同時合併[[抗反轉錄病毒藥物|抗反轉錄病毒藥物]]治療。本品的給藥方式是口服藥錠或藥水<ref name="AHFS2016">{{cite web|title=Entecavir|url=https://www.drugs.com/monograph/entecavir.html|accessdate=28 November 2016|publisher=The American Society of Health-System Pharmacists|archiveurl=https://web.archive.org/web/20161220224057/https://www.drugs.com/monograph/entecavir.html|archivedate=20 December 2016}}</ref>，口服生物可用率可達100％，但當消化道有食物存在時會影響到它的作用效果，因此會建議病人於空腹時服用。(source?)

恩替卡韋屬於[[抗反轉錄病毒藥物|核苷酸類反轉錄酶抑制劑]]（NRTIs）<ref name="AHFS2016" /><ref>{{Cite book|title=Chronic Viral Hepatitis: Diagnosis and Therapeutics|url=https://books.google.ca/books?id=o67J8smzgHEC&pg=PA34|publisher=Springer Science & Business Media|date=2009-06-13|isbn=978-1-59745-565-7|language=en|first=Kirti|last=Shetty|first2=George Y.|last2=Wu|page=34|access-date=2020-01-11|archive-date=2018-08-28|archive-url=https://web.archive.org/web/20180828203253/https://books.google.ca/books?id=o67J8smzgHEC&pg=PA34|dead-url=no}}</ref>，藉由競爭GTP，能夠阻斷HBV DNA polymerase 鹼基引發、負股轉錄及合成正股DNA的作用，避免 B 肝病毒增生<ref name="AHFS2016" />，此外研究已經證實其主要的Transporter為ENT1和OAT2<ref>{{Cite journal|title=Roles of organic anion transporter 2 and equilibrative nucleoside transporter 1 in hepatic disposition and antiviral activity of entecavir during non-pregnancy and pregnancy|url=https://pubmed.ncbi.nlm.nih.gov/31166004/|last=Ma|first=Zhiyuan|last2=Lu|first2=Shuanghui|date=09 2019|journal=British Journal of Pharmacology|issue=17|doi=10.1111/bph.14756|volume=176|pages=3236–3249|issn=1476-5381|pmc=6692639|pmid=31166004|last3=Sun|first3=Dongli|last4=Bai|first4=Mengru|last5=Jiang|first5=Ting|last6=Lin|first6=Nengming|last7=Zhou|first7=Hui|last8=Zeng|first8=Su|last9=Jiang|first9=Huidi}}</ref>。

<!-- Side effects and mechanism -->
服用entecavir常見的副作用有[[頭痛|頭痛]]、[[噁心|噁心]]、[[高血糖|高血糖]]和[[腎功能|腎功能]]低下。如果患者停藥，可能引發嚴重的副作用如{{le|肝腫大|Hepatomegaly}}、[[乳酸性酸中毒|血中乳酸值上升]]和[[肝炎|肝炎]]等<ref name="AHFS2016" />。[[妊娠|妊娠]]期間使用本品目前顯示安全，並有文獻指出使用本藥品不會提高新生兒先天缺陷的機率。亦有其他動物實驗證實懷孕後期的賀爾蒙濃度對entecavir的抗病毒作用並沒有影響，在懷孕後期使用此藥時可能可以考慮不調整劑量。然而entecavir對孕婦抗HBV的人體試驗資料尚不充足，還有賴後續的臨床研究來證實。

<!-- History and culture -->
2005 年，恩替卡韋通過核可用於醫療用途<ref name="AHFS2016" />。本品列名於[[世界衛生組織基本藥物標準清單|世界衛生組織基本藥物標準清單]]之中，認可為基本[[醫療系統|醫療系統]]最安全有效的藥物之一<ref name="WHO19th">{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|accessdate=8 December 2016|date=April 2015|work=World Health Organization|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016}}</ref>。截至 2015 年，[[美國|美國]]才有本品的[[通用名藥物|學名藥]]上市<ref name="Ric2015">{{cite book|last1=Hamilton|first1=Richart|title=Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition|date=2015|publisher=Jones & Bartlett Learning|isbn=9781284057560|page=76}}</ref>；2016 年，通常一個月份的批發價約在 392 美元<ref>{{cite web|title=NADAC as of 2016-11-30|url=https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-11-30/rfpb-hznz|accessdate=6 December 2016|publisher=Centers for Medicare and Medicaid Services|archiveurl=https://web.archive.org/web/20161130035804/https://data.medicaid.gov/Drug-Prices/NADAC-as-of-2016-11-30/rfpb-hznz|archivedate=30 November 2016}}</ref>。

==外部連結==
*[http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0010112/ PubMed Health page on Entecavir] {{Wayback|url=http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0010112/ |date=20131112165923 }}
*[https://web.archive.org/web/20121029115449/http://www.baraclude.com/ Baraclude U.S. website]

== 參考資料 ==
{{reflist}}

{{抗DNA病毒药物}}
{{抗病毒药物}}

[[Category:百时美施贵宝|Category:百时美施贵宝]]
[[Category:核苷类似物逆转录酶抑制剂|Category:核苷类似物逆转录酶抑制剂]]
[[Category:嘌呤|Category:嘌呤]]
[[Category:环戊基化合物|Category:环戊基化合物]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]
[[Category:烯烃衍生物|Category:烯烃衍生物]]
[[Category:肝毒素|Category:肝毒素]]